$PM

UBS raises Philip Morris stock price target to $201 on earnings beat

UBS raised Philip Morris' (PM) price target to $201 from $193, citing a 3% Q3 2026 earnings beat. PM's shares trade near the new target. The company reported adjusted EPS of $2.36 and revenue of $11.4B, with smoke-free products driving growth. However, smoke-free sales missed estimates, and PM revised its fiscal 2026 profit growth outlook downward.

Original reporting
Published Oct 22, 2026, 2:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 2:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PM
Bullish
high confidence
Mentioned
$PM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PMBullishMed
01

Why it matters

The earnings beat and UBS price‑target raise provide fresh, material data that could move the stock modestly higher.

02

Market read

Earnings beat and analyst target raise create a short‑term bullish catalyst for PM.

03

What to watch

Potential regulatory risks in smoke‑free product markets could temper the rally.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Philip Morris reported Q3 2026 earnings with EPS $2.36 and revenue $11.4 B, beating consensus, and highlighted strong combustibles performance and smoke‑free product growth.

Company-level read

Ticker impact

$PMBullishHigh confidence
Context

UBS raised its price target on Philip Morris International to $201 after the company reported Q3 2026 earnings that beat estimates.

Expected impact

likely modest upside as the market prices in the higher target

Evidence & confidence

The earnings beat and new target provide fresh, material information for a large‑cap stock.

Market effects

Positive earnings may lift the tobacco sector and related consumer staples peers.

U.S. market may see slight gains in defensive stocks.

Limited to markets tracking large‑cap consumer staples.

Counterpoint

The neutral rating suggests limited upside; investors may wait for further guidance before buying.

Key entities

  • Philip Morris International

    Tobacco company reporting earnings and receiving a higher price target.

  • UBS

    Raised price target to $201 and maintained a Neutral rating.

Related articles

$PMMedAI 8/10

Philip Morris International Inc (PM) (Q3 2026) Earnings Call Highlights: Record $5

Philip Morris International (PM) reported Q3 2026 results with organic net revenue growth of 7.1% and adjusted operating income growth of 10.5%, exceeding $5 billion. Smoke-free products drove growth, with IQOS and Veev shipments up. The company faces cost pressures from geopolitical conflicts, impacting full-year EPS growth. Guidance was lowered to the midpoint or lower half of the range. Operating cash flow is expected to reach approximately $13.5 billion.

$THighAI 8/10

AT&T Raises 2026 Outlook as Dell AI Adoption Tops 6,500

AT&T reported Q3 revenue growth of 5.3% to $32.3B, raised 2026 adjusted EPS outlook to ~$2.40. Philip Morris saw Q3 revenue rise 5.5% to $11.4B, adjusted EPS up 5.4% to $2.36. Moody's reported 1% revenue growth to $2.023B, reaffirmed 2026 adjusted EPS forecast of $16.50-$17.00. Dell announced AI adoption by 6,500 enterprises.

$PMMedAI 8/10

Philip Morris International Inc. Q3 2026 Earnings Call Summary

Philip Morris reported Q3 2026 growth, with smoke-free products offsetting combustible declines. IQOS grew 10.8% (ex-Japan/Poland), Marlboro hit 11.4% international share, and ZYN saw 13% U.S. volume growth. Margins expanded 130 bps. Guidance: 5-7% organic revenue growth, 7.5-9.5% EPS growth (currency-neutral). Geopolitical and supply chain issues pose risks.